High frequency of multidrug-resistant Escherichia coli from cattle in the Cerrado and Pantanal biomes of Brazil

The indiscriminate use of antimicrobials has led to the emergence of resistant bacteria, especially pathogenic strains of Escherichia coli, which are associated with diseases in animals and humans. The aim of the present study was to characterize E. coli isolates in calves with regards to the presence of virulence genes and investigate the resistance of the isolates to different antimicrobials. Between 2021 and 2023, 456 fecal samples were collected from calves in the Pantanal and Cerrado biomes of the state of Mato Grosso do Sul, Brazil. All samples were subjected to microbiological analysis and disc diffusion antibiogram testing. The polymerase chain reaction method was used to detect virulence genes. Bacterial growth was found in 451 of the 456 samples and biochemically identified as Escherichia coli. All 451 isolates (100%) exhibited some phenotypic resistance to antimicrobials and 67.62% exhibited multidrug resistance. The frequency of multidrug-resistant isolates in the Cerrado biome was significantly higher than that in the Pantanal biome (p = 0.0001). In the Cerrado, the most common pathotype was Shiga toxin-producing Escherichia coli (STEC) (28%), followed by toxigenic Escherichia coli (ETEC) (11%), enterohemorrhagic Escherichia coli (EHEC) (8%) and enteropathogenic Escherichia coli (EPEC) (2%). In most cases, the concomitant occurrence of pathotypes was more common, the most frequent of which were ETEC + STEC (33%), ETEC + EHEC (15%) and ETEC + EPEC (3%). The STEC pathotype (30%) was also found more frequently in the Pantanal, followed by EHEC (12%), ETEC (9%) and EPEC (6%). The STEC pathotype had a significantly higher frequency of multidrug resistance (p = 0.0486) compared to the other pathotypes identified. The frequency of resistance was lower in strains from the Pantanal biome compared to those from the Cerrado biome. Although some factors are discussed in this paper, it is necessary to clarify the reasons for this difference and the possible impacts of these findings on both animal and human health in the region.

Clinical safety of lauric acid for cattle and its in vitro and in vivo efficacy against Rhipicephalus microplus

The aim of the present study was to test the in vitro acaricidal activity of saturated fatty acids (hexanoic, octanoic, decanoic, lauric, myristic, palmitic, octadecanoic, eicosanoic, docosanoic and tetracosanoic) against Rhipicephalus microplus and select a candidate compound for the subsequent determination of its clinical safety for mice and bovines as well as its in vivo efficacy (ethical clearance number 507/2013). None of the compounds exhibited in vitro larvicidal effectiveness, but acaricidal effectiveness was greater than 95 % in the adult immersion test at 40 mg/ml (hexanoic, octanoic, decanoic, lauric, myristic, palmitic and eicosanoic acids). After a second AIT evaluation of serial concentrations of the fatty acids, lauric and myristic acids were selected for the safety and in vivo efficacy assays. No adverse effect was found in the local lymph node assay in mice treated with lauric or myristic acid. Moreover, no clinical signs of systemic poisoning or dermatological, hematological or biochemical abnormalities were found in cattle after the topical application of 1 % lauric acid. In the dose determination test, the 1% solution of this compound exhibited 86% efficacy in cattle naturally infested by a field population of Rhipicephalus microplus susceptible to all chemical groups, except synthetic pyrethroids. The efficacy of 1 % lauric acid was 53.4 % in the dose confirmation test performed on another herd with a field R. microplus population resistant to all chemical groups of acaricides. In conclusion, fatty acids are potential bioactive compounds for the control of R. microplus. Topically applied lauric acid (C12) exhibits in vivo acaricide activity against adults, nymphs and larvae of R. (B) microplus and is safe for cattle.

Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003

The prevalence of cytomegalovirus (CMV) infections ranges between 50% and 85% in adults in the United States, and its epidemiology varies in different regions of the world and between socioeconomic and age groups. In Portugal, no study has been carried out to date to determine the prevalence of CMV in the general population. Under the second National Serological Survey conducted in continental Portugal in 2001–2002, we estimated the prevalence of individuals with antibodies to CMV using indirect immunofluorescence to detect virus-specific IgG. The population sample included 2,143 individuals of both sexes and different ages from all 18 districts in Portugal. The national seroprevalence of CMV was determined as 77%. We analysed the proportion of CMV IgG by sex, age group and district of residence. This was the first nationally representative study of seroprevalence of CMV in Portugal. The results of the study indicate that CMV infection is highly prevalent in the population and occurs mainly in the first years of life.

Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003

Binary file ES_Abstracts_Final_ECDC.txt matches

A strategy to increase and assess vaccine coverage in the north of Portugal

In the Northern Health Region of Portugal, vaccine coverage is measured by checking and studying individual vaccination records in health centres. Each year from 2001-2004, birth cohorts completing 2, 6 and 14 years of age were selected for assessment. Data collection occurred on January the following year and meetings with district immunisation coordinators took place every March. For all vaccines and birth cohorts considered, vaccine coverage values observed in the north of Portugal were excellent. In this paper, we make comparisons with published international data on vaccine coverage and discuss validity issues; we believe that no serious biases have affected the validity of our vaccine coverage data but comparisons with international data must be addressed with caution; the methods we used have been useful in increasing vaccination coverage.

[The use of endoprosthesis in superior vena cava syndrome caused by lung neoplasms]

We present six cases of superior vena cava syndrome caused by a malignant tumor that were treated by percutaneous endoprostheses. The technique is described and the results evaluated. In one case there was acute thrombosis of the endoprosthesis that was treated by urokinase. No other complications were observed. A patient died one month later due to progression of the tumor. The remaining cases were asymptomatic for longer than 6 months. It was concluded that endoprostheses for superior vena cava syndrome are efficient, with quick improvement of the symptomatology.

[The usefulness of bronchofibroscopy in the diagnosis of lung neoplasms in patients with protracted pneumonia]

Fiber-optic bronchoscopy is commonly performed in patients with non resolving pneumonia to exclude endobronchial neoplastic tumours. Radiographic resolution of community-acquired pneumonia is variable, depending on several factors, as the causative agent or host dependent factors. Therefore, the decision to perform a bronchoscopy is sometimes empirical. To describe our experience in this subject we reviewed the clinical registrations and the bronchoscopy protocols of 123 consecutive patients with community-acquired pneumonia that did not show significant radiographic resolution after at least ten days of antibiotic therapy. A histological diagnosis of malignant neoplasia was obtained in 5.6% of the cases. All patients were males, more than 55 years old and heavy smokers (more than 40 pack/year). The comparison between this risk group and the other patients showed statistically significant differences in age and tobacco consumption. Symptom duration, haemoglobin, leukocytes, sedimentation rate, renal or hepatic tests were not significantly different in both groups. We recommend that fiber-optic bronchoscopy must be performed early in heavy smokers, patients over 55 years of age with slow or non resolving pneumonia. In non-smokers or younger patients, it should only be performed after 4 to 8 weeks, unless clinical symptoms justify an earlier observation.